Inhibikase Therapeutics, Inc. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company at a critical juncture, having successfully consolidated its resources into a single, high-stakes bet on IKT-001. The financial data confirms a strong current cash position, but also highlights the aggressive spending required to maintain a global Phase 3 trial. The alignment with the FDA on the 505(b)(2) pathway is a clear victory for the company, potentially shaving years off the development timeline and reducing the risk of unforeseen safety issues. Ultimately, Inhibikase has stripped away the noise of its legacy pipeline to present investors with a pure-play binary event. The outcome of the IMPROVE-PAH study will determine whether the company's capital-efficient bridge leads to a commercial breakthrough or a total collapse. Investors are now weighing the strength of the institutional lock-up against the inherent volatility of a clinical-stage biotech with no current revenue.